<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488176</url>
  </required_header>
  <id_info>
    <org_study_id>RNN/94/07KE</org_study_id>
    <nct_id>NCT00488176</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis</brief_title>
  <official_title>Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of montelukast and cetirizine on allergic
      inflammation measured by exhaled nitric oxide concentration in children with seasonal
      allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the pollen season children with seasonal allergic rhinitis without concomitant asthma
      are at risk of having allergic inflammation in the lower respiratory tract. About 60% of
      children with seasonal allergic rhinitis present bronchial hyperresponsiveness and signs and
      symptoms of asthma.

      The aim of this study is to compare the effect of montelukast and cetirizine on allergic
      inflammation measured by exhaled nitric oxide concentration in children with seasonal
      allergic rhinitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exhaled nitric oxide concentration</measure>
    <time_frame>baseline (first visit), after 4 weeks (second visit) and after 6 weeks from second visit (third visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms score (based on PAQLQ), bronchial hyperresponsiveness with methacholine, spirometry, PEFR measurements</measure>
    <time_frame>baseline (first visit), after 4 weeks (second visit) and after 6 weeks from second visit (third visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monteluksat sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cetirizine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>montelukast sodium and cetirizine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>montelukast sodium</description>
    <arm_group_label>1</arm_group_label>
    <other_name>montelukast sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetirizine</intervention_name>
    <description>cetirizine</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast and cetirizine</intervention_name>
    <description>montelukast and cetirizine</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical symptoms of seasonal allergic rhinitis during last two seasons, moderate and
             severe according to ARIA guidelines

        Exclusion Criteria:

          -  diagnosis of bronchial asthma

          -  allergy to perennial allergens

          -  specific immunotherapy

          -  other chronic diseases

          -  tobacco smoking

          -  acute respiratory tract infection

          -  excluded drugs: inhaled and systemic glucocorticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Violetta Ścibiorek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwona Stelmach, MD PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Violetta Ścibiorek, MD</last_name>
    <phone>00 48 42 6895972</phone>
    <email>alergol@kopernik.lodz.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violetta Ścibiorek, MD</last_name>
      <phone>00 48 42 689 59 72</phone>
      <email>alergol@kopernik.lodz.pl</email>
    </contact>
    <investigator>
      <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Universtity of Lodz</investigator_affiliation>
    <investigator_full_name>Iwona Stelmach</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>seasonal allergic rhinitis</keyword>
  <keyword>children</keyword>
  <keyword>montelukast</keyword>
  <keyword>cetirizine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

